Market icon
Finanzen·Börsengänge

Kailera Therapeutics IPO Closing Market Cap

Market icon
Finanzen·Börsengänge

Kailera Therapeutics IPO Closing Market Cap

Apr. 16

Apr. 16

Apr. 17

Apr. 17

Apr. 16

Apr. 16

Apr. 17

Apr. 17

2.1B+ 52%

<1.7B 49%

1.7B–1.8B 49%

1.8B–1.9B 48%

Polymarket
NEU

2.1B+ 52%

<1.7B 49%

1.7B–1.8B 49%

1.8B–1.9B 48%

Polymarket
NEU

<1.7B

$0 Vol.

49%

1.7B–1.8B

$0 Vol.

49%

1.8B–1.9B

$0 Vol.

48%

1.9B–2.0B

$0 Vol.

24%

2.0B–2.1B

$0 Vol.

24%

2.1B+

$0 Vol.

52%

No IPO before June 2026

$0 Vol.

24%

This market will resolve based on Kailera Therapeutics’ market capitalization at the closing price on its first day of trading. As of market creation, the IPO is scheduled to price on April 17 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026". Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency. It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day. If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently. The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page. If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket. The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading. In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.

This market will resolve based on Kailera Therapeutics’ market capitalization at the closing price on its first day of trading.

As of market creation, the IPO is scheduled to price on April 17 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".

Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.

It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.

If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.

The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.

If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.

The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.

In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Volumen
$0
Enddatum
17. Apr. 2026
Markt eröffnet
Apr 14, 2026, 5:05 PM ET

Resolver

0x69c47De9D...
This market will resolve based on Kailera Therapeutics’ market capitalization at the closing price on its first day of trading. As of market creation, the IPO is scheduled to price on April 17 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026". Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency. It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day. If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently. The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page. If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket. The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading. In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
This market will resolve based on Kailera Therapeutics’ market capitalization at the closing price on its first day of trading. As of market creation, the IPO is scheduled to price on April 17 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026". Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency. It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day. If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently. The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page. If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket. The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading. In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.

This market will resolve based on Kailera Therapeutics’ market capitalization at the closing price on its first day of trading.

As of market creation, the IPO is scheduled to price on April 17 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".

Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.

It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.

If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.

The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.

If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.

The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.

In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Volumen
$0
Enddatum
17. Apr. 2026
Markt eröffnet
Apr 14, 2026, 5:05 PM ET

Resolver

0x69c47De9D...
This market will resolve based on Kailera Therapeutics’ market capitalization at the closing price on its first day of trading. As of market creation, the IPO is scheduled to price on April 17 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026". Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency. It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day. If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently. The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page. If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket. The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading. In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.

Vorsicht bei externen Links.

Häufig gestellte Fragen

„Kailera Therapeutics IPO Closing Market Cap" ist ein Prognosemarkt auf Polymarket mit 7 möglichen Ergebnissen, bei dem Händler Anteile auf Basis ihrer Einschätzung kaufen und verkaufen. Das aktuell führende Ergebnis ist „2.1B+" mit 52%, gefolgt von „<1.7B" mit 49%. Die Preise spiegeln Echtzeit-Wahrscheinlichkeiten der Community wider. Ein Anteilspreis von 52¢ bedeutet, dass der Markt diesem Ergebnis eine Wahrscheinlichkeit von 52% zuweist. Diese Quoten ändern sich laufend, wenn Händler auf neue Entwicklungen reagieren. Anteile am richtigen Ergebnis können bei Marktauflösung für jeweils $1 eingelöst werden.

„Kailera Therapeutics IPO Closing Market Cap" ist ein neu erstellter Markt auf Polymarket, gestartet am Apr 14, 2026. Als früher Markt haben Sie die Gelegenheit, zu den ersten Händlern zu gehören, die die Quoten setzen und die ersten Preissignale des Marktes etablieren. Sie können diese Seite auch als Lesezeichen speichern, um Volumen und Handelsaktivität zu verfolgen, während der Markt an Fahrt gewinnt.

Um auf „Kailera Therapeutics IPO Closing Market Cap" zu handeln, durchsuchen Sie die 7 verfügbaren Ergebnisse auf dieser Seite. Jedes Ergebnis zeigt einen aktuellen Preis, der die implizierte Wahrscheinlichkeit des Marktes darstellt. Um eine Position einzunehmen, wählen Sie das Ergebnis, das Sie für am wahrscheinlichsten halten, wählen Sie „Ja" um dafür oder „Nein" um dagegen zu handeln, geben Sie Ihren Betrag ein und klicken Sie auf „Handeln". Liegt Ihr gewähltes Ergebnis bei Marktauflösung richtig, zahlen Ihre „Ja"-Anteile jeweils $1 aus. Liegt es falsch, zahlen sie $0. Sie können Ihre Anteile auch jederzeit vor der Auflösung verkaufen.

Der aktuelle Favorit für „Kailera Therapeutics IPO Closing Market Cap" ist „2.1B+" mit 52%, was bedeutet, dass der Markt diesem Ergebnis eine Wahrscheinlichkeit von 52% zuweist. Das nächstliegende Ergebnis ist „<1.7B" mit 49%. Diese Quoten werden in Echtzeit aktualisiert, wenn Händler Anteile kaufen und verkaufen. Schauen Sie regelmäßig vorbei oder speichern Sie diese Seite als Lesezeichen.

Die Auflösungsregeln für „Kailera Therapeutics IPO Closing Market Cap" definieren genau, was passieren muss, damit jedes Ergebnis als Gewinner erklärt wird – einschließlich der offiziellen Datenquellen zur Bestimmung des Ergebnisses. Sie können die vollständigen Auflösungskriterien im Abschnitt „Regeln" auf dieser Seite über den Kommentaren einsehen. Wir empfehlen, die Regeln vor dem Handeln sorgfältig zu lesen, da sie die genauen Bedingungen, Sonderfälle und Quellen festlegen.